RACHEL HAWES: Open Payments
NPI 1609455765 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,739 in 126 payments from 40 companies in 2025. Trend: 2023 $1,956 · 2024 $2,475 · 2025 $2,739
Food & beverage: $2,640Education: $99
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 12 | $276 |
| Merck Sharp & Dohme LLC | 7 | $174 |
| PFIZER INC. | 10 | $171 |
| AstraZeneca Pharmaceuticals LP | 8 | $163 |
| Janssen Biotech, Inc. | 7 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $157 |
| GlaxoSmithKline, LLC. | 7 | $119 |
| ABBVIE INC. | 6 | $113 |
| Daiichi Sankyo Inc. | 4 | $100 |
| SOBI, INC | 5 | $99 |
Products named: KEYTRUDA, KISQALI, FRUZAQLA, XTANDI, Vonjo, REBLOZYL, OPDIVO, EPKINLY.
Industry payments across AL — which companies pay providers there.
